Green tea, B12, and folic acid: a new weapon against HPV?
NCT ID NCT06285357
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study is testing whether a daily supplement containing green tea extract (EGCG), folic acid, and vitamin B12 can help women clear a persistent high-risk HPV infection in the cervix. About 100 women with a positive HPV test but no serious cell changes will take the supplement for several months. The goal is to see if the supplement increases the chance of the body clearing the virus naturally.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- EGCG (green tea extract), folic acid, and vitamin B12
- What this could lead to
- If it works, this could point toward a simple, non-invasive way to help the body clear high-risk HPV infections and reduce the risk of cervical cancer.
- What could go wrong
- This is a very early pilot study with only 100 participants, so results may not be conclusive. Dietary supplements are not a proven treatment for HPV, and the effect may be small or absent.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2024
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
25 to 65 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * HR-HPV DNA test positivity Exclusion Criteria: * No HSIL
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Azienda Ospedaliero-Universitaria di Modena
RECRUITINGModena, Modena, 41124, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a daily supplement help the body fight off HPV?
- At-Home HPV tests could save lives of women with HIV
- New immune therapy aims to train body to clear HPV
- Could a tiny HPV shot still protect? small study tests lower dose
- New Self-Sampling and digital colposcopy could speed up cervical cancer detection
- Could a smaller HPV vaccine dose still protect adults?